{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:07:32Z","timestamp":1761523652517,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T00:00:00Z","timestamp":1615852800000},"content-version":"vor","delay-in-days":380,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.ccell.2020.02.009","type":"journal-article","created":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T14:09:31Z","timestamp":1584367771000},"page":"263-265","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Breaking Down the Barriers to Define and Treat NK\/T Cell Lymphoma"],"prefix":"10.1016","volume":"37","author":[{"given":"Bethany","family":"Mundy-Bosse","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Weinstock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccell.2020.02.009_bib1","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins","volume":"32","author":"Bollard","year":"2014","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2020.02.009_bib2","doi-asserted-by":"crossref","first-page":"6010","DOI":"10.1158\/0008-5472.CAN-19-0615","article-title":"Integrated Pan-Cancer Map of EBV-Associated Neoplasms Reveals Functional Host-Virus Interactions","volume":"79","author":"Chakravorty","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2020.02.009_bib3","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s11899-015-0292-z","article-title":"The Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment","volume":"10","author":"Gru","year":"2015","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.ccell.2020.02.009_bib4","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ng.3358","article-title":"Exome sequencing identifies somatic mutations of DDX3X in natural killer\/T-cell lymphoma","volume":"47","author":"Jiang","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ccell.2020.02.009_bib5","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1038\/ncomms7025","article-title":"Activating mutations of STAT5B and STAT3 in lymphomas derived from \u03b3\u03b4-T or NK cells","volume":"6","author":"K\u00fc\u00e7\u00fck","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2020.02.009_bib6","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.ccell.2020.02.009_bib7","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1182\/blood-2019-125017","article-title":"Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma","volume":"134","author":"Moskowitz","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2020.02.009_bib8","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/s41375-018-0324-5","article-title":"Genomic and transcriptomic landscapes of Epstein-Barr virus in extranodal natural killer T-cell lymphoma","volume":"33","author":"Peng","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.ccell.2020.02.009_bib9","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ccell.2020.02.005","article-title":"Genomic and Transcriptomic Characterization of Natural-Killer T-cell Lymphoma","volume":"37","author":"Xiong","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2020.02.009_bib10","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/s41588-019-0436-5","article-title":"Genome sequencing analysis identifies Epstein-Barr virus subtypes associated with high risk of nasopharyngeal carcinoma","volume":"51","author":"Xu","year":"2019","journal-title":"Nat. Genet."}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610820300982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610820300982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:02:57Z","timestamp":1761523377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610820300982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S1535610820300982"],"URL":"https:\/\/doi.org\/10.1016\/j.ccell.2020.02.009","relation":{},"ISSN":["1535-6108"],"issn-type":[{"type":"print","value":"1535-6108"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Breaking Down the Barriers to Define and Treat NK\/T Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2020.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2020.02.005","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}